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Abstract
Background: Plantar heel pain (PHP) is common and impacts negatively on physical function and quality of life.
Initial treatment usually comprises analgesia and self-management advice (SMA), with referral to a physiotherapist
or podiatrist recommended only when symptoms persist. Systematic reviews highlight limitations of existing
evidence for the effectiveness of exercises and orthoses. The objective of the TREADON pilot and feasibility trial was
to inform the design of a future main trial to compare the clinical and cost-effectiveness of self-management
advice (SMA), individualised exercises and foot orthoses for PHP.
Methods: This was a four-arm randomised feasibility and pilot trial with 12-week follow-up. Adults aged ≥ 18 years
with PHP were identified from primary care by general practice consultation, retrospective general practice medical
record review or a population survey. Participants were randomised to either (i) SMA, (ii) SMA plus individualised
exercises (SMA-exercises), (iii) SMA plus prefabricated foot orthoses (SMA-orthoses) or (iv) SMA plus combined
individualised exercises and prefabricated foot orthoses (SMA-combined). Feasibility outcomes were recruitment;
retention; intervention adherence, credibility and satisfaction; performance of three potential primary outcome
measures (pain numeric rating scale (NRS), Foot Function Index-pain subscale (FFI-pain), Manchester Foot Pain and
Disability Index-pain subscale (MFPDI-pain)); and parameters for informing the main trial sample size calculation.
Results: Eighty-two participants were recruited. All three identification methods met the target number of participants.
Retention at 12 weeks was 67%. All interventions were successfully delivered as per protocol. Adherence (range over 12
weeks 64–100%) and credibility (93%) were highest in the SMA-combined arm. Satisfaction with treatment was higher
for the three clinician-supported interventions (SMA 29%, SMA-exercises 72%, SMA-orthoses 71%, SMA-combined 73%).
Responsiveness (baseline to 12 weeks) was higher for FFI-pain (standardised response mean 0.96) and pain NRS (1.04)
than MFPDI-pain (0.57). Conservative sample size parameter estimates for standard deviation were pain NRS 2.5, FFI-
pain 25 and MFPDI-pain 4, and baseline-outcome correlations were 0.5–0.6, 0.4 and < 0.3, respectively.
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Conclusions: We demonstrated the feasibility of conducting a future main randomised clinical trial comparing the
clinical and cost-effectiveness of SMA, exercises and/or foot orthoses for PHP.
Trial registration number: ISRCTN 12160508. Prospectively registered 5th July 2016.
Keywords: Randomised trial, Pilot and feasibility trial, Plantar heel pain/fasciitis, Foot orthoses, Exercise
Key messages regarding feasibility
1) What uncertainties existed regarding the feasibility?
To inform the design of a future main randomised
trial of self-management advice, exercise and orthoses
for plantar heel pain, we compared the success of three
different participant identification methods, determined
the number of trial arms and which interventions to test,
compared the performance of three potential primary
outcome measures and investigated key parameters to
inform the sample size calculation. We investigated
whether physiotherapists and podiatrists were able to de-
liver the interventions to protocol in a similar way.
2) What are the key feasibility findings?
All three identification methods met the target num-
ber of participants. Loss-to-follow-up rates were accept-
able but would need to be improved in a future main
trial. The interventions achieved high levels of adher-
ence, satisfaction and credibility and were delivered suc-
cessfully by both physiotherapists and podiatrists. The
three potential primary outcome measures were compar-
able, although the Manchester Foot Pain and Disability
Index had lower responsiveness. Key information to de-
termine the sample size calculation was obtained.
3) What are the implications of the feasibility findings
for the design of the main study?
A future main randomised clinical trial testing these inter-
ventions is feasible and acceptable. Either the pain numeric
rating scale or the Foot Function Index would be suitable as
the primary outcome measure for the future main trial.
Background
Plantar heel pain (PHP) describes a range of conditions
affecting the plantar heel of unknown aetiology [1]. It is
typically aggravated by weight-bearing after prolonged
rest. PHP affects 10% of adults during their lifetime,
impairing quality of life, physical function, mobility and
ability to work [2–4]. PHP is usually self-limiting, al-
though symptoms can take 1 to 2 years to resolve [5].
Primary care treatment approaches comprise analgesia
and self-management advice regarding rest, footwear,
heel pads and weight loss [5–7]. Referral to a physiother-
apist or podiatrist is recommended if symptoms persist
[5, 8]. However, symptoms can become chronic and per-
sistent, leading to impaired quality of life, physical in-
activity and weight gain [4, 9].
Physiotherapists and podiatrists typically use lower limb
exercises and/or foot orthoses to treat PHP [10–15], al-
though the evidence supporting these interventions is lim-
ited. Systematic reviews highlight that many trials are
limited by small sample sizes, poor methodological quality
and short duration of follow-up [16–18]. Recent reviews
of foot orthoses reached conflicting conclusions about
their effectiveness relative to sham orthoses [16, 17], and
our recent network meta-analysis found limited evidence
about which conservative treatment is the most effective
for PHP [18]. Hence, a large, methodologically robust
multicentre randomised trial that compares exercises and
orthoses for the management of PHP over a longer
follow-up period is needed. We undertook the TREA
DON (TReatments of Exercise AnD Orthotic devices for
plaNtar heel pain) feasibility and pilot trial to (i) compare
the success of three different identification methods, (ii)
determine the number of trial arms and which interven-
tions to test, (iii) determine the primary outcome measure,
(iv) inform the sample size calculation and (v) examine
potential prognostic baseline factors.
Methods
Design
This was a pragmatic, four-parallel-arm, multicentre,
randomised, feasibility and pilot trial undertaken in 12
general practices and 2 NHS trusts. The trial protocol is
publically available [19].
Participants
Participants were community-dwelling adults aged ≥ 18
years identified from participating general practices. In-
clusion criteria were self-reported localised pain under
the heel aggravated by weight-bearing, worst when first
standing or after rest, especially on getting up in the
morning or following periods of prolonged sitting; symp-
tom duration of at least 4 weeks; minimum pain score of
2 on a 0–10 numeric rating scale (NRS); owning/access
to a mobile or landline telephone; and being able and
willing to participate and provide written informed con-
sent. Exclusion criteria were inflammatory arthritis (e.g.
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rheumatoid arthritis, ankylosing spondylitis, reactive
arthritis, systemic lupus erythematosus, gout, psoriatic
arthritis); fibromyalgia; serious pathologies (e.g. malig-
nancy, trauma, infection); treatment for PHP by a
physiotherapist or podiatrist currently or in the last 3
months; corticosteroid injection into the affected foot in
the last 3 months; previous or awaiting surgery on the
affected foot; allergy to common orthotic device mate-
rials (e.g. adhesives, latex, sock dyes, certain shoe types);
or unwillingness/inability to undertake interventions or
attend clinics, complete follow-up questionnaires in Eng-
lish or receive text messages/phone calls.
Participant identification and recruitment
Potential participants were identified by three methods:
(i) General practice consultation (nine general
practices): general practitioners (GP) were alerted
by electronic ‘pop-up’ reminders when they entered
a relevant PHP diagnostic code. Patients were
screened for potential eligibility by the GP.
Potentially eligible, interested patients were given a
participant information leaflet (PIL) and asked for
written consent to be contacted by the research
team. GPs provided advice and, if appropriate, pain
relief medication but no other interventions.
Patients were posted a trial information pack
(invitation letter, PIL, consent form, baseline
questionnaire and pre-paid return envelope).
(ii) Retrospective medical record review (MRR) (11
general practices): patients who had consulted
their GP for foot/ankle pain in the preceding
year were identified from medical records. A
broad range of symptom codes was used because
foot/ankle consultations are often not coded with
specific diagnostic labels such as PHP [20]. GPs
screened lists to exclude potentially vulnerable
patients. Remaining patients were mailed a brief
information leaflet, screening survey, consent to
contact form and pre-paid return envelope. The
survey asked respondents to indicate the location
of pain on a validated foot manikin (© The Uni-
versity of Manchester 2000. All rights reserved)
[21, 22] and complete questions regarding foot
pain, demographic details and eligibility. Non-
responders were sent reminders after 2 and 4
weeks.
(iii)Population survey (one general practice): a postal
questionnaire was mailed to all adults registered at
one general practice to identify those who had heel
pain but had not consulted in the preceding year.
GPs screened lists to exclude potentially vulnerable
patients. Patients were mailed as described in (ii).
Patients identified via (ii) and (iii) who provided con-
sent to contact and who appeared eligible were then
posted a trial information pack.
Patients sent a trial information pack by any of the
three methods were telephoned to explain the trial, con-
firm eligibility and obtain consent to participate. The
completed consent form and baseline questionnaire were
returned by postal mail.
Randomisation and concealment
On receipt of the completed consent form and baseline
questionnaire, participants were randomly allocated to
an intervention by administrators using the Keele Clin-
ical Trials Unit secure randomisation system. Allocation
was concealed from the researchers. Stratified block ran-
domisation was undertaken (fixed block size 4), blocked
by treatment site. Participants were randomised on an
equal basis to one of the following interventions:
(i) Self-management advice (SMA) booklet: control
arm
(ii) SMA booklet plus individualised exercise (SMA-
exercises)
(iii)SMA booklet plus pre-fabricated foot orthoses
(SMA-orthoses)
(iv) SMA booklet plus individualised exercise and pre-
fabricated foot orthoses (SMA-combined)
Owing to the nature of the interventions, participants
could not be blind to treatment allocation. Due to slow
recruitment initially, and with agreement from the Trial
Steering Committee and funder, randomisation to the
SMA control arm ceased following allocation of 11 par-
ticipants to this arm. Subsequent participants were ran-
domised on a 1:1:1 basis to the three clinician-supported
intervention arms to ensure sufficient data were col-
lected to assess the feasibility of these interventions. Par-
ticipants were informed of their allocation in writing.
Interventions
SMA control arm
Participants were posted a bespoke SMA booklet about
PHP, which included stretching exercises reproduced
with permission from the Versus Arthritis PHP exercise
sheet and supplemented with specific advice and infor-
mation including self-help messages about pain relief,
footwear, rest and weight loss [23].
SMA-exercises
Participants were given the SMA booklet. The treating
clinician (a physiotherapist or podiatrist) assessed point
tenderness under the heel by pressing the thumb into
the underside of the heel (medial calcaneal tubercle) and
medial longitudinal arch, and documented foot posture
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using the Foot Posture Index-6 (FPI-6) [24]. They could
receive an additional generic lower limb assessment of
alignment and function if deemed appropriate. Exercise
selection was informed by the degree of clinically ob-
served muscle tightness, weakness and functional limita-
tion. The exercises were drawn from best available
evidence [10, 25–29] and discussion with local clinicians
during a pre-trial workshop, and included foot-specific
stretches/exercises targeting the plantar fascia and in-
trinsic foot muscles, ankle-related muscle groups such as
soleus and gastrocnemius and other lower limb muscle
groups (Additional file 1). Participants were instructed
how to perform the exercises, advised on dose (fre-
quency, intensity, type and timing) and given an indivi-
dualised and detailed exercise sheet to support their
home exercise programme. The individualised exercise
programme was progressed at follow-up consultations
informed by subjective and objective re-assessment.
SMA-foot orthoses
Participants were given the SMA booklet and were
assessed as described above. The orthotic device was
chosen based on the degree of static rearfoot eversion
assessed by the FPI-6 (Additional file 2). Participants
were instructed how to fit the device and advised to
wear it for 1 h per day, gradually increasing by 1 h per
day up to at least 4 h per day, and given an individua-
lised and detailed orthosis information sheet. The orth-
osis could be altered during subsequent consultations
according to participants’ self-reported tolerance or clin-
ical presentation.
SMA-combined
Participants were given the SMA booklet, underwent
clinical assessment and received both exercise and orth-
oses interventions as described above.
Exercise and orthosis interventions were delivered over
up to six treatment sessions over 12 weeks by a NHS
physiotherapist or podiatrist trained to deliver all interven-
tion protocols. Clinicians attended a 2-day training work-
shop prior to the start of recruitment and treatment,
covering carrying out the standardised assessment, deliv-
ery of the interventions in line with the agreed protocol
and documentation including case report forms and ad-
verse event reporting, supplemented by a comprehensive
clinician manual, providing clear treatment protocols.
Participants were asked not to use other treatments
during the 12-week intervention period, other than
medication if this had been provided by their GP.
Follow-up and outcomes
Data collection
Participants rated their average PHP intensity in the last
7 days (0–10 NRS, anchored 0 = ‘no pain’ and 10 =
‘worst pain imaginable’). Pain NRS were collected weekly
for 12 weeks by text message or brief telephone call.
Other outcomes were collected by postal questionnaire
at 12 weeks. Non-responders to the questionnaire were
sent a reminder text message/postcard after 10 days and
a second questionnaire after a further five days, and then
telephoned by a research nurse to collect key outcomes.
Non-responders unable to be contacted by telephone
were mailed a brief minimum data questionnaire. Partic-
ipants randomised to the clinician-supported interven-
tion arms recorded adherence, engagement with the
intervention and adverse events in a weekly paper diary.
Process outcomes
The feasibility of the patient identification methods was
assessed by comparing the number identified, eligible
and recruited, rates of recruitment and retention, and by
evaluating the cost and effort of each method.
Participant-reported engagement with and adherence to
each intervention was assessed including a global inter-
vention adherence scale (5-point Likert scale; doing exer-
cises/wearing orthoses as often as advised over the last
week; strongly agree/agree/not sure/disagree/strongly dis-
agree), number of weeks adherence, the duration and fre-
quency of completing exercises and/or wearing foot
orthoses and reasons for non-adherence. Participant-
reported intervention credibility and satisfaction were
assessed. Fidelity of intervention delivery and participant
attendance at intervention sessions were collected using
clinician-completed case report forms. Participating clini-
cians’ evaluations of intervention delivery, including ac-
ceptability of the FPI-6, views on the number and
duration of intervention sessions, ease of generation of
individualised exercise regimen sheets and use of the orth-
otic devices were assessed via a short online survey and fa-
cilitated workshop at the end of the trial.
Clinical outcomes
Three potential primary outcome measures for the fu-
ture main trial were evaluated:
(i) PHP 0-10 pain intensity NRS. Further evaluation
was undertaken exploring time to participants’ re-
port of being ‘significantly better’ defined as a NRS
score of 0 or 1 recorded over two consecutive
weeks.
(ii) Change in the Foot Function Index pain subscale
(FFI-pain) from baseline to 12 weeks, a validated
nine-item self-administered questionnaire [30, 31].
(iii)Change in the Manchester Foot Pain and Disability
Index pain subscale (MFPDI-pain) from baseline to
12 weeks, a validated seven-item self-administered
questionnaire [32].
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Completion rates of secondary outcome measures
were assessed. Presence of PHP (yes/no) was assessed at
baseline, in weekly text messages and at 12 weeks. First
step pain (0–10 NRS), foot function (FFI disability and
activity restriction subscales, MFPDI function subscale)
[30–32], health-related quality of life (EQ-5D-5L) [33],
current employment status and work performance (on
average, to what extent has your heel pain affected your
performance at work over the past month? 0–10 NRS
anchored 0 = ‘not at all’ and 10 = ‘so bad I am unable to
do my job’) and absenteeism (number of days lost) were
assessed at baseline and 12 weeks. Participant impres-
sion of change in heel pain over 12 weeks (six response
options: completely recovered, much better, better, no
change, worse and much worse) and healthcare utilisa-
tion (including use of analgesics) were self-reported by
participants at 12 weeks. Adverse events were reported
by participants in the weekly diary and 12-week ques-
tionnaire and also by GPs and treating physiotherapists
and podiatrists.
Sample size
We aimed to derive sufficiently precise estimates for the
future main trial around: (i) overall adherence to inter-
vention protocols (90% one-sided lower confidence
bound), (ii) observed completion rates of the FFI and
MFPDI (90% one-sided lower confidence bound), and
(iii) the standard deviation (SD) for the pain NRS, FFI
and MFPDI (at the level of an inflation factor of 1.1 in
the point estimate of the feasibility SD) providing 80–
90% confidence in attaining the nominal power of the
main trial [34]. We estimated that we would need to re-
cruit 80 participants (20 per arm) over a 9-month
period.
Statistical analysis
Results were analysed descriptively and there was no
emphasis on hypothesis-testing. At baseline and follow-
up, participants’ descriptive data were summarised using
median (inter-quartile range (IQR)) or mean (SD), and
frequency counts and percentages for categorical vari-
ables overall and by intervention arm.
Rates of eligibility and recruitment (with 80%, 90% and
95% confidence intervals (CI), number of consenting/
randomised participants per month) and retention
(returned 12-week questionnaires, number of weekly
texts) were estimated, in total and stratified by identifica-
tion method. Participants’ baseline characteristics were
examined and compared to ineligible and non-
consenting patients and between the three identification
methods.
Fidelity and adherence to intervention protocols were
compared between arms including attendance at inter-
vention sessions, adherence to exercise and orthosis
interventions and intervention credibility and satisfac-
tion, summarising categorical variables using counts and
percentages. Clinician survey and workshop data were
analysed descriptively.
Performance of the three potential primary outcome
measures was assessed using response, item completion
rates, floor/ceiling effects and responsiveness (standar-
dised response mean) [35]. Analysis of outcome per-
formance comprised (i) mean pain scores (standard
deviation) overall and for each week of follow-up and/or
12 week follow-up, (ii) life-table and Kaplan-Meier sur-
vival plots with an emphasis on mean survival times for
pain NRS time-to-event data, and (iii) the percentage of
participants meeting recognised minimal clinically im-
portant difference (MCID) thresholds (where available),
i.e. medians of 1.7 and 12 for pain NRS and FFI-pain re-
spectively [36, 37].
Effect size, standard deviation, baseline-outcome cor-
relation, inter-correlation of pain NRS scores (for re-
peated measures) and dropouts to inform the sample
size calculation for the main trial were calculated.
Associations between baseline variables (first episode of
PHP, bilateral PHP, older age, duration of PHP, baseline
pain score, morning pain (0–10 NRS), employment status
(employed/not employed), baseline general health (EQ-
5D-5L)) and the three clinical pain outcomes were calcu-
lated using Spearman’s correlation; coefficients exceeding
a pre-agreed cut-off (rs ≥ 0.3) were considered suitable for
taking forward as potential baseline covariates in
regression-based adjustment within the main trial.
The feasibility of collecting healthcare resource use
and quality of life data was determined by examining re-
sponse and item completion rates. Costs were derived by
linking intervention costs and healthcare resource use
costs [38–40] obtained from self-reported data with
available unit costs. Aggregated and disaggregated costs
were descriptively compared between intervention arms.
Final analysis used STATA version 14.2 (StataCorp
LLC, College Station, TX) and was completed after the
final 12-week follow-up.
Patient and public involvement
This trial was developed with research users with PHP
who provided feedback on the funding application and
protocol, particularly the content of the exercises and
the choice of orthoses. They also advised on the poten-
tial primary outcome measures for the future main trial
which were evaluated in the pilot and feasibility trial and
the content of participant-facing paperwork and text
messages. The information and advice provided in the
SMA booklet was developed with input from four people
with PHP and members of Keele’s Patient and Public In-
volvement and Engagement group over three 1–2 h
workshops. One patient representative served on the
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independent trial steering committee, playing a full part
in monitoring trial progress and conduct. Research users




Between November 2016 and July 2017, we recruited 82
participants from 251 eligible people invited (median age
55 years (IQR 48, 67), 44% male), giving a recruitment
uptake of 32.7% (95%, 90% and 80% lower 1-sided CILLs
of 26.9%, 27.8% and 28.8%, respectively). Age and sex of
participants and non-participants (n = 169) were similar
(55.8 vs. 54.8 years; female 56.1% vs. 61.5%). All three
identification methods recruited their target number of
participants: GP consultation 37/70 potentially eligible
(52.9%; 80% 1-sided CILL 44.5%); MRR 22/69 (31.9%;
24.5%); and population survey 23/112 (20.5%; 15.6%)
(Fig. 1). Estimated recruitment rates per year from each
identification method were: GP consultation 6.0/10,000
(80%CI 4.8, 7.5) [0.5 per month], MRR 2.6/10,000 (1.9,
3.4) [0.2 per month] and population survey 27.1/10,000
(20.1, 35.8) [at least 2.3 per month]. The mean cost of
each identification method per recruited participant was
£63.84 for GP consultation, £165.22 for MRR and £1063
for the population survey. Withdrawal rates were 13.5%
(5/37), 4.5% (1/22) and 17.4% (4/23) for GP consultation,
MRR and the population survey, respectively. Partici-
pants recruited by the population survey were older, had
milder symptom severity and were less commonly fe-
male or employed, whereas those recruited via GP
consultation had heel pain of shorter duration and less
commonly had bilateral heel pain (Table 1).
Recruitment was initially slow. After consultation with
the Trial Steering Committee and funder, we halted ran-
domisation to the SMA arm after 11 participants had
been allocated to that arm to ensure there were suffi-
cient participants in the three clinician-supported inter-
vention arms to allow intervention fidelity to be assessed
fully. However, by increasing the pooled practice popula-
tion from which participants were identified from 60,000
predicted to 86,000 (12 general practices), we were able
to recruit our target sample size of at least 80 partici-
pants. In total, 11 participants were randomised to SMA,
23 to SMA-exercises, 24 to SMA-orthoses and 24 to
SMA-combined (Fig. 1). Baseline characteristics between
arms were similar, although those randomised to SMA
had longer duration heel pain and were more commonly
employed and reported a previous episode of heel pain.
The SMA-orthoses arm had higher mean baseline FFI
pain score and both the SMA-orthoses and SMA-
exercises arms less commonly had bilateral heel pain
(Table 1).
Intervention adherence, fidelity, satisfaction and
credibility
Sixty-one participants in the three clinician-supported
intervention arms received their allocated treatment
(85.9%; 90% 1-sided lower CILL 80.6%). They attended a
mean of 2.3 consultations (SMA-exercises = 2.3, SMA-
orthoses = 1.9, SMA-combined = 2.8). Trial clinicians (7
physiotherapists, 5 podiatrists) successfully delivered
Fig. 1 Recruitment, eligibility and retention by participant identification method
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interventions in routine clinical appointments (Table 2).
Participating clinicians found the exercise and orthosis
prescription options sufficiently flexible; however, some
physiotherapists lacked confidence adjusting orthoses
and felt that additional training would be beneficial.
Some clinicians felt that balance and eccentric calf exer-
cise options could have been helpful and the ability to
provide participants with more than one pair of their
prescribed orthotic device may improve adherence, par-
ticularly as seasonal changes in footwear may impact
adherence.
More participants in the SMA-combined (exercise:
13/14, 91%; orthosis: 13/15, 87%) and SMA-orthoses
(12/17, 71%) arms agreed/strongly agreed they had
adopted advice given than in the SMA control (3/6,
50%) or SMA plus exercise (6/13, 46%) arms.







Attended, n (%) 20/22 (91) 20/20 (100) 22/22 (100)
Did not attend, n (%) 2/22 (9) 0/20 (0) 0/22 (0)
Cancelled, n (%) 0/22 (0) 0/20 (0) 0/22 (0)
Plantar heel pain confirmed, n (%) 18/19 (95)3 18/20 (90) 18/18 (100)4
Total appointments attended (mean) 42 (1.91) 46 (2.30) 62 (2.82)
Total appointments including non-attenders (mean) 43 (1.95) 49 (2.45) 66 (3.00)
















































































3.5 (2.3)3 2.6 (1.9)2 3.5 (4.0)2 3.3 (3.4)2
Received allocated treatment, n (%) 21/22 (95) 19/20 (95) 21/22 (95)
Nominated left foot as trial foot, n (%) 8/19 (42)3 12/20 (60) 8/22 (36)
Orthoses
Orthotic device received(Vectorthotic, Salfordinsole Firm, or Salfordinsole Flex) 15, 3, 13 – 15, 5, 11
Additional modification to orthoses, n (%) 10/19 (53)3 – 10/21 (48)1
Participant fitted orthoses correctly, n (%) 18/19 (95)3 – 20/21 (95)1
Discussed orthoses care instructions with participant, n (%) 19/19 (100)3 – 21/21 (100)1
Exercise
Adequate exercise technique, n (%) – 17/17 (100)3 22/22 (100)
Home exercise leaflet provided, n (%) – 16/17 (94)3 22/22 (100)
Sum cost (£) of AHP visits [mean scheduled visits x cost per visit] (mean cost
per patient)b
£1155.84 (£52.54) £1317.12 (£65.86) £1774.08 (£80.64)
Sum cost (£) of insoles [no. receiving insoles x cost of insoles]c £273 – £273
Grand Total intervention GBP cost (mean cost per patient) £1428.84 (£64.95)b £1317.12 (£65.86)b £2047.08 (£93.05)b
aNumber accounting for early withdrawals: orthosis n = 2, exercise n = 3, combined n = 2. 1–5 Numbers noted after summary statistics relate to the number of
missing/ambiguous data (no number denotes complete responses to that measure)
bUnit cost for Allied health professionals costed at band 6, £26.88 for 30–45-min consultation (£43 per hour [37])
cMean intervention cost based on mean cost of physiotherapist/podiatrist visits plus a typical £13 cost for pre-fabricated orthotic insoles for the proportion of
patients in the orthotic and combined intervention groups that received the insoles
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Response to weekly self-report diaries ranged from 42
to 63% across the three clinician-supported interven-
tion arms (Table 3). Self-reported adherence was
highest in the SMA-combined arm (range over 12
weeks: SMA-exercises 40–83%, SMA-orthoses 57–
87%, SMA-combined 64–100%). ‘Lack of time’ or ‘for-
getting’ were the main reasons given for lower adher-
ence in the SMA-exercises arm, although adherence
to exercise in the SMA-combined arm was high (80–
100%). Participant satisfaction with care received, re-
sults of treatment/information received and percep-
tion of intervention credibility were higher in the
three clinician-supported intervention arms than the
SMA arm (Table 4).
Adverse events
There were 57 expected, non-serious adverse events
in the SMA-exercises arm, 83 in the SMA-orthoses
arm and 77 in the SMA-combined arm. For exercise,
counts for SMA-exercises and SMA-combined were
new/different foot pain/tiredness/stiffness (n = 22, n =
5 respectively); cramp or soreness in the feet or calf
muscle (7, 6); bruising in the feet or calf muscle (0,
0); soreness in other joints (15, 15); and other (13,
Table 3 Self-reported adherence in the SMA-exercises, SMA-orthoses and SMA-combined arms



































1 10/12 (83%) 7 (6, 7) 2 (2, 3) b(n = 2) 12/15 (80%) 5 (4, 7) 3 (2, 4) b(n = 1) c(n = 1) d(n = 1)
2 9/12 (75%) 7 (6, 7) 2 (2, 3) b(n = 3) c(n = 1) 13/15 (87%) 6 (4, 7) 4 (2, 4) c(n = 1)
3 7/12 (58%) 7 (4, 7) 2 (1, 3) a(n = 1) b(n = 2) c(n = 2) 10/14 (71%) 5 (2, 7) 4 (2, 4) a(n = 1) b(n = 1) d(n = 1)
4 5/11 (45%) 6 (5, 7) 2 (1, 3) b(n = 4) c(n = 1) d(n = 1) 11/15 (73%) 6 (4, 7) 4 (3, 4) c(n = 1) d(n = 2)
5 5/11 (45%) 5 (3, 7) 1 (1, 3) b(n = 6) 10/14 (71%) 6 (2, 7) 4 (4, 4) b(n = 1) c(n = 1) d(n = 1)
6 7/11 (64%) 7 (4, 7) 2 (1, 3) b(n = 3) d(n = 1) 9/15 (60%) 6 (1, 7) 4 (3, 4) b(n = 1) c(n = 1)
7 8/11 (73%) 7 (4, 7) 2 (1, 3) b(n = 2) c(n = 1) 8/14 (57%) 6 (2, 7) 4 (3, 4) d(n = 1)
8 7/11 (64%) 7 (6, 7) 2 (1, 3) b(n = 3) c(n = 1) 10/14 (71%) 5 (4, 7) 4 (2, 4) c(n = 1) d(n = 2)
9 6/11 (55%) 6 (4, 7) 2 (1, 2) a(n = 2) b(n = 2) d(n = 2) 9/13 (69%) 5 (2, 7) 4 (2, 4) a(n = 1) c(n = 1)
10 8/11 (73%) 6 (5, 7) 2 (1, 3) a(n = 1), b(n = 3) 11/14 (79%) 6 (2, 7) 4 (2, 4) a(n = 1) c(n = 1)
11 5/10 (50%) 7 (4, 7) 2 (1, 3) a(n = 2) b(n = 5) 9/13 (69%) 6 (3, 7) 4 (4, 4) b(n = 1) c(n = 1) d(n = 1)
12 4/10 (40%) 5 (2, 6) 2 (1, 3) a(n = 1) b(n = 4) d(n = 2) 8/14 (57%) 6 (2, 7) 4 (4, 4) a(n = 2) d(n = 1)
SMA-combined
1 10/11 (91%) 7 (5, 7) 2 (2, 2) b(n = 1) c(n = 1) 10/11 (91%) 7 (5, 7) 4 (3, 4) Missing
2 10/11 (91%) 6 (5, 7) 2 (2, 3) d(n = 1) 10/11 (91%) 7 (5, 7) 4 (3, 4) c(n = 1)
3 11/11 (100%) 7 (5, 7) 2 (2, 2) n/a 11/11 (100%) 7 (6, 7) 4 (3, 4) n/a
4 10/11 (91%) 6 (5, 7) 2 (2, 2) d(n = 1) 8/11 (73%) 7 (5, 7) 3 (2, 4) Missing
5 9/11 (82%) 5 (4, 7) 2 (1, 3) d(n = 1) 10/11 (91%) 7 (5, 7) 4 (2, 4) c(n = 1)
6 9/10 (90%) 5 (4, 7) 2 (1, 2) d(n = 1) 7/10 (70%) 5 (2, 7) 4 (2, 4) c(n = 2) d(n = 1)
7 10/12 (83%) 5 (5, 7) 2 (2, 2) b(n = 1) d(n = 2) 9/12 (75%) 6 (4, 7) 4 (2, 4) c(n = 2) d(n = 1)
8 11/12 (92%) 6 (4, 7) 2 (2, 2) b(n = 1) d(n =1) 10/12 (83%) 6 (4, 7) 4 (3, 4) c(n = 2)
9 11/12 (92%) 7 (5, 7) 2 (2, 2) b(n = 1) 9/12 (75%) 6 (4, 7) 4 (2, 4) c(n = 2)
10 9/11 (82%) 5 (3, 7) 2 (2, 2) b(n = 2) 8/11 (73%) 5 (2, 7) 4 (2, 4) c(n = 1)
11 9/11 (82%) 6 (4, 7) 2 (2, 2) b(n = 1) d(n = 1) 7/11 (64%) 5 (2, 7) 3 (2, 4) c(n = 1)
12 8/10 (80%) 6 (4, 7) 2 (2, 2) b(n = 1) d(n = 2) 7/10 (70%) 6 (3, 7) 3 (2, 4) Missing
Numbers are frequency counts n/n (percent); median (IQR)
aSummary excluded those who answered ‘Yes’ to ‘exercise (or, wearing insoles), completed as prescribed over the week’; proportions of the following reasons: a.
because my symptoms were better; b. I forgot/lack of time; c. because the exercises (orthotics) were too difficult (uncomfortable)/made symptoms worse; and
d. other
b‘Strongly agree’ and ‘Agree’ as yes; ‘Not sure’, ‘Disagree’ and ‘Strongly disagree’ as no. NA not applicable, SMA self-management advice
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13). For orthoses, counts for SMA-orthoses and
SMA-combined were cramp or soreness in the feet or
calf muscle (32, 18); bruising/blister/skin irritation in
the feet (21, 4); soreness in other joints (26, 13); falls
(0, 0); and other (4, 3).
Follow-up and outcomes
The follow-up rate over 12 weeks was 55/82 (67.1%; 90%
and 80% lower 1-sided CILLs of 60.4% and 62.7% re-
spectively), ranging between 63 and 75% across interven-
tion arms (Table 5). Because of a technical fault, only
Table 4 Participant satisfaction and perceived credibility with treatment
SMA SMA-exercises SMA-orthoses SMA-combined
Satisfaction (1): ‘How satisfied are you with the care received?’
Very satisfied 1 (14.3) 6 (40.0) 10 (55.6) 10 (66.7)
Quite satisfied 2 (28.6) 5 (33.3) 4 (22.2) 4 (26.7)
No opinion 1 (14.3) 3 (20.0) 3 (16.7) 0 (0.0)
Not very satisfied 1 (14.3) 0 (0.0) 1 (5.6) 0 (0.0)
Not at all satisfied 2 (28.6) 1 (6.7) 0 (0.0) 1 (6.7)
Satisfaction (2): ‘How satisfied are you with the results of treatment?’
Very satisfied 0 (0.0) 2 (13.3) 5 (27.8) 8 (53.3)
Quite satisfied 2 (28.6) 9 (60.0) 8 (44.4) 3 (20.0)
No opinion 2 (28.6) 2 (13.3) 2 (11.1) 1 (6.7)
Not very satisfied 1 (14.3) 1 (6.7) 3 (16.7) 1 (6.7)
Not at all satisfied 2 (28.6) 1 (6.7) 0 (0.0) 2 (13.3)
Satisfaction (3): ‘How satisfied are you with the information received concerning heel problem?’
Very satisfied 1 (14.3) 7 (46.7) 7 (38.9) 8 (53.3)
Quite satisfied 3 (42.9) 6 (40.0) 9 (50.0) 5 (33.3)
No opinion 1 (14.3) 2 (13.3) 2 (11.1) 1 (6.7)
Not very satisfied 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.7)
Not at all satisfied 2 (28.6) 0 (0.0) 0 (0.0) 0 (0.0)
Credibility (1): ‘Information booklet or treatment has helped heel pain’
Very confident 0 (0.0) 2 (15.4) 7 (41.2) 6 (42.9)1 / 7 (46.7)2
Quite confident 2 (28.6) 8 (61.5) 6 (35.3) 6 (42.9) / 3 (20.0)
Neither 3 (42.9) 2 (15.4) 2 (11.8) 0 (0.0) / 3 (20.0)
Not very confident 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.1) / 0 (0.0)
Not at all confident 2 (28.6) 1 (7.7) 2 (11.8) 1 (7.1) / 2 (13.3)
Credibility (2): ‘Recommending the information or treatment to others’
Very confident 1 (14.3) 3 (23.1) 8 (47.1) 8 (57.1)1 / 7 (46.7)2
Quite confident 2 (28.6) 8 (61.5) 6 (35.3) 4 (28.6) / 3 (20.0)
Neither 1 (14.3) 1 (7.7) 1 (5.9) 0 (0.0) / 2 (13.3)
Not very confident 1 (14.3) 0 (0.0) 1 (5.9) 1 (7.1) / 1 (6.7)
Not at all confident 2 (28.6) 1 (7.7) 1 (5.9) 1 (7.1) / 2 (13.3)
Credibility (3): ‘Did the information in booklet or treatment seem to make sense to you?’
Very Sensible 3 (42.9) 5 (38.5) 6 (35.3) 7 (50.0)1 / 8 (53.3)2
Quite Sensible 2 (28.6) 6 (46.2) 8 (47.1) 6 (42.9) / 6 (40.0)
No opinion 2 (28.6) 2 (15.4) 2 (11.8) 0 (0.0) / 0 (0.0)
Not very sensible 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.1) / 0 (0.0)
Not at all sensible 0 (0.0) 0 (0.0) 1 (5.9) 0 (0.0) / 1 (6.7)
Numbers are n (%). Frequency counts do not always sum to corresponding group totals due to some missing data. 1 relates to perceived credibility of exercises; 2
relates to perceived credibility of orthotics (within SMA-combined arm)
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Table 5 Summary of outcome measures and healthcare utilisation at 12 weeks by treatment arm











Average Pain NRS (last 7 days)a,c 3 (2, 4)1 5 (3, 7) 3 (2, 4) 3 (2, 4) 2 (1, 4)1
Pain on getting out of beda 4 (2, 7)2 6 (3, 9) 4 (3, 6)1 5 (2, 7)1 2 (1, 9)
Heel pain todayb 36 (65.5) 4 (57.1) 11 (73.3) 13 (72.2) 8 (53.3)
Heel(s) affectedb
Left 13 (28.3)9 3 (42.9) 3 (25.0)3 6 (35.3)1 1 (10.0)5
Right 18 (39.1)9 2 (28.6) 5 (41.7)3 6 (35.3)1 5 (50.0)5
Both 15 (32.6)9 2 (28.6) 4 (33.3)3 6 (35.3)1 4 (40.0)5
Ache or pain lasting one day or longer in past monthb 36 (69.2)3 6 (85.7) 11 (78.6)1 12 (70.6)1 7 (50.0)1
FFI-Paina,d 28 (15, 50)14 38 (31, 74)1 24 (16, 48)7 36 (20, 51)4 18 (6, 24)2
FFI-Disabilitya 12 (1, 35)3 19 (12, 67) 17 (7, 48)1 7 (0, 32)2 1 (0, 13)
FFI-Activity Restrictiona 1 (0, 3)1 2 (0, 18) 2 (0, 2)1 2 (0, 4) 0 (0, 1)
FFI-Overalla 37 (21, 80)17 52 (45, 164)1 40 (27, 95)8 40 (26, 82)6 21 (8, 36)2
MFPDI-Functiona 16 (13, 20) 14 (13, 21) 16 (12, 20) 16 (14, 21) 14 (10, 19)
MFPDI-Paina,e 12 (10, 14) 12 (9, 16) 13 (10, 15) 12 (10, 14) 10 (9, 12)
MFPDI-Personal Appearancea 3 (2, 4)19 2 (2, 3)1 3 (2, 4)5 4 (3, 4)6 2 (2, 3)7
MFPDI-Overalla 29 (23, 38)19 29 (25, 32)1 34 (26, 36)5 36 (27, 39)6 23 (22, 28)7
EuroQol EQ5Da .74 (.65, .84)4 .63 (.51, .84)1 .74 (.72, .80) .74 (.64, .84)2 .84 (.71, 1.00)1
Global change, n (%)
Completely recovered 4 (7) 0 (0) 1 (7) 0 (0) 3 (20)
Much better 19 (35) 0 (0) 4 (27) 9 (50) 6 (40)
Better 20 (36) 4 (57) 8 (53) 6 (33) 2 (13)
No change 9 (16) 2 (29) 2 (13) 3 (17) 2 (13)
Worse 2 (4) 0 (0) 0 (0) 0 (0) 2 (13)
Much worse 1 (2) 1 (14) 0 (0) 0 (0) 0 (0)
Healthcare utilisation (other than study intervention)
Additional health provider visits
Attended an NHS/private health care provider for heel
pain, n (%) #1
9 (16) 1 (14) 3 (20) 2 (11) 3 (20)
GP (NHS), visit count 7 2 3 0 2
Physiotherapist (NHS/Private), visit count 15/2 1/0 9/0 1/0 4/2
Podiatrist or Chiropodist (NHS/Private), visit count 5/1 0/0 0/1 2/0 3/0




£80.64 (£4.48) £315.92 (£21.06)
Investigations and surgery
Received an investigation or treatment for heel pain, n
(%)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Referred for surgery for heel pain, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Had surgery for heel pain, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Had inpatient stay for heel pain, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Medications—prescriptions
Prescribed tablet medication for heel pain, n (%) # #2 3 (5) 0 (0) 2 (13) 0 (0) 1 (7)
Ibuprofen (Nurofen, Brufen), n 1 0 1 0 0
Codeine, n 1 0 1 0 0
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Table 5 Summary of outcome measures and healthcare utilisation at 12 weeks by treatment arm (Continued)










Cocodamol (Solpadol, Kapake), n 1 0 0 0 1
Sub-Cost (GBP) total (overall mean) £9.78 (£0.18) £0 £5.81 (£0.39) £0 £3.97 (£0.26)
Medications–over-the-counter (OTC)
Bought over-the-counter medication, n (%) #3 15 (27) 4 (57) 3 (20) 5 (28) 3 (20)
Paracetamol, n 6 (mean cost,
£3.81)
2 1 2 1
Ibuprofen, n 9 (mean cost,
£6.37)
3 2 3 1
Co-codamol, n 1# 0 0 0 1
Creams/gels/sprays, n 3 (mean cost,
£2.98)
2 0 0 1
Sub-Cost (GBP) total (overall mean) £93.10 (£1.69) £32.69(£4.67) £16.55 (£1.10) £26.73 (£1.49) £17.13 (£1.14)
Indirect (lost productivity)
No. having time off work (absenteeism), n (days) #4 1 (4) 0 (0) 1 (4) 0 (0) 0 (0)
Sub-cost (GBP) total (overall mean) £375.42 (£6.83) £0 (£0) £375.42(£25.03) £0 (£0) £0 (£0)
Work performance (presenteeism) score, mean (SD) #5 1.9 (2.6) 2.3# (3.9) 2.1 (2.0) 2.5 (3.0) 0.6 (1.8)









Comparison of aggregated mean costs (GBP)
Direct healthcare cost (NHS + OTC) £82.42 £19.08 £92.67 £70.92 £115.51
Societal cost
Healthcare + Work-absenteeism £89.25 £19.08 £117.70 £70.92 £115.51
Healthcare + absenteeism + presenteeism £195.02 £191.28 £229.63 £163.00 £175.78
#1 Unit cost sources (per visit): GP (£37), allied health professionals band 6 (£26.88 per 30–45 minute-consultation) (private costed as NHS due to lack of available
source data on private unit costs)) [38]. #2 Prescription cost ibuprofen 200mg 48 tabs (£1.84), codeine phosphate/co-codamol 30 mg/100 mg 100 tabs (£3.97) [39]
#3 Self-reported OTC costs; ^co-codamol cost was not recorded (hence taken to be the same as prescription cost). #4 one person reported taking time off work
for heel pain; occupation aligned to SOC2010 code 8111 indicating mean hourly wage £11.14 (mean weekly hours worked 42.1); hence 33.7 hours absence
assumed over 4 days; cost £375.42 [40]. #5 Mean hourly wage across all employees in 2017 was £16.16 and mean hours worked was 33.3. Presenteeism costs
were extrapolated: number of baseline employees x (average of baseline and follow-up work performance scores)/10 x 33.3 x 16.16.
aMedian (interquartile range)
bAs number (percent) 1–19 Number noted after summary statistics relate to the number of missing/ambiguous data (no number denotes complete 55 responses).
For the multi-item measures item-completion numbers, the count × completed-items summary were: FFI-Pain (1 × 0, 1 × 1, 1 × 3, 1 × 6, 9 × 7, 1 × 8, 41 × 9); FFI-
Disability (1 × 7, 2 × 8, 52 × 9); FFI-Activity Restriction (1 × 4, 54 × 5); MFPDI-Function (55 × 10); MFPDI-Pain (55 × 7); MFPDI-Personal Appearance (8 × 0, 11 × 1,
36 × 2).
cFor NRS-Pain, mean (SD) values were: SMA, mean = 5.3 (SD 2.5); SMA + E, mean = 2.9 (SD 1.3); SMA + O, mean = 3.2 (SD 2.3); SMA + C, mean = 2.7 (SD = 3.0).
The weighted average SD = 2.3 (1-sided 80%CIUL = 2.5; 1-sided 90%CIUL = 2.7; 1-sided 95%CIUL = 2.8)
dFor FFI-Pain, mean (SD) values were SMA, mean = 48.3 (SD 27.6); SMA-exercises, mean = 29.6 (SD 16.5); SMA-orthoses, mean = 35.0 (SD 21.4); SMA-combined,
mean = 25.2 (SD = 27.1). The weighted average SD = 23.5 (1-sided 80%CIUL = 26.2; 1-sided 90%CIUL = 27.6; 1-sided 95%CIUL = 28.9)
eFor MFPDI-Pain, mean (SD) values were SMA, mean = 12.7 (SD 4.0); SMA-exercises, mean = 12.6 (SD 3.5); SMA-orthoses, mean = 12.5 (SD 2.9); SMA-combined,
mean = 11.6 (SD = 4.2). Weighted average SD = 3.6 (1-sided 80%CIUL = 3.9; 1-sided 90%CIUL = 4.1; 1-sided 95%CIUL = 4.3)











Responsivenessb With global change With EQ5D change
Spearman’s correlation AUC (95% CI)c Spearman’s correlation
NRS change 5.9 (1.9) 3.3 (2.4) 2.6 (2.5) 1.04 0.60 0.88 (0.79, 0.96) 0.87
FFI-pain change 50.6 (17.7) 32.8 (23.9) 21.6 (22.4) 0.96 0.74 0.84 (0.69, 0.99) 0.71
MFPDI-pain change 14.0 (2.8) 12.3 (3.5) 1.7 (3.0) 0.57 0.57 0.72 (0.58, 0.67) 0.75
aChange from baseline to 12 week
bResponsiveness statistic (standardised response mean = mean change in score / SD of change scores; usually interpreted against the benchmarks ≤ 0.2: small,
0.5: moderate, ≥ 0.8: large [35])
cGlobal change dichotomised as (completely recovered or much better / somewhat better or no change or somewhat worse or much worse)
Chesterton et al. Pilot and Feasibility Studies            (2021) 7:92 Page 13 of 18
the first 55 participants received all weekly text mes-
sages. Of 842 total SMS texts sent, there were 582 (69%)
responses. Further, 66/82 (80%) responded to 4 or more
messages, 60/82 (73%) to at least 6 messages and 38/82
(46%) to 9 or more messages. Item completion rates for
MFPDI-pain (100%) were higher than for FFI-pain
(85%).
All three pain scales were normally distributed and
symmetric at baseline with absolute skewness values <
0.5 and similar mean and median values (pain NRS
mean = 5.8, median = 6.0; FFI-Pain 50.7, 53.0; MFPDI-
Pain 13.7, 13.0). Floor-and-ceiling baseline distributional
concerns were small (floor: pain NRS 0-1 recorded by 2
(2.5%), FFI-pain 0-10 by 1 (2.2%) and MFPDI-pain 7-8
by 0 (0%); ceiling: pain NRS 9-10 by 4 (5%), FFI-pain 90-
100 and MFPDI-pain 20-21 both 0 (0%)). Responsiveness
from baseline to 12 weeks was higher for FFI-pain (0.96)
and pain NRS (1.04) than MFPDI-pain (0.57) (Table 6).
Correlation with global rating score and EQ5D was
higher for FFI-pain change and pain NRS than MFPDI-
pain change.
Over 12 weeks, the overall mean reduction in pain
NRS was 2.6 (SD 2.5), FFI-pain 21.6 (SD 22.4) and
MFPDI-pain 1.7 (SD 3.0). Furthermore, 9/82 (11%) re-
ported being significantly better within the 12-week
follow-up (9/55 (16%) of participants who received all
weekly text messages) (Table 7). For change in weekly
pain NRS, absolute and standardised between-group
mean differences scores provided signal of possible effect
for the two orthosis arms over the SMA booklet only
arm (Fig. 2a). Signal of efficacy was also provided for all
three intervention arms versus control (the SMA arm)
on pain NRS at 12 weeks: absolute mean difference
(standardised difference) 2.1 (1.1) for SMA-exercises, 3.2
(1.7) for SMA-orthoses and 3.2 (1.7) for SMA-combined.
For change in FFI-Pain at 12 weeks, the absolute (stan-
dardised) mean differences compared to the SMA arm
were − 4 (− 0.2) for SMA-exercises, 10 (0.6) for SMA-
orthoses and 16 (1.0) for SMA-combined. The median
MCID of 1.7 for the pain NRS at 12 weeks was achieved
by 34/54 (63%) (SMA 3/7 (43%); SMA-exercises 10/15
(67%), SMA-orthoses 12/18 (67%), SMA-combined 9/14
(64%)). For FFI-pain, the median MCID of 12 was
achieved at 12 weeks by 17/28 (61%) (SMA 2/4 (50%),
SMA-exercises 4/7 (57%), SMA-orthoses 7/10 (70%),
SMA-combined 4/7 (57%)). Pain trajectories were simi-
lar across the intervention arms (Fig. 2a).
For informing the sample size for the absolute
between-group difference in pain NRS scores, conserva-
tive parameter estimates were SD 2.5, baseline-outcome
correlation 0.5–0.6, repeated-measures correlation 0.7
and ≥ 80% of participants responding to at least half of
text messages received. For the absolute differences in
the FFI-pain and MFPDI-Pain, estimates were SD 26
and 4, baseline-outcome correlation 0.4 and < 0.3 and
follow-up 50% and 67% respectively.
Table 7 Pain NRS by treatment arm (for n = 55 participants who received all SMS-text-messages)

































BL 55/55(100) 5.6 (1.9) NA 5.8 (2.1) NA 4.7 (1.5) NA 5.8 (2.0) NA 6.1 (1.6) NA
W1 40/55 (73) 5.2 (2.3) NA 5.0 (3.2) NA 4.3 (2.1) NA 4.8 (2.1) NA 6.3 (1.9) NA
W2 35/55 (64) 5.1 (2.1) 0 (0) 5.8 (2.7) 0 (0) 4.2 (2.2) 0 (0) 4.9 (1.6) 0 (0) 5.6 (2.1) 0 (0)
W3 34/55 (62) 4.4 (2.4) 2 (4) 4.2 (2.4) 0 (0) 3.8 (2.1) 1 (7) 3.1 (2.1) 1 (8) 6.2 (2.2) 0 (0)
W4 40/55 (73) 4.4 (1.9) 3 (6) 5.0 (1.6) 0 (0) 3.8 (2.1) 2 (13) 3.8 (2.0) 1 (8) 5.1 (1.8) 0 (0)
W5 38/55 (69) 4.4 (2.3) 3 (6) 4.5 (2.4) 0 (0) 4.3 (2.5) 2 (13) 3.6 (2.2) 1 (8) 5.2 (2.3) 0 (0)
W6 40/55 (73) 3.7 (2.1) 4 (8) 4.3 (2.7) 0 (0) 3.3 (2.0) 2 (13) 3.5 (2.4) 2 (15) 3.9 (1.7) 0 (0)
W7 37/55 (67) 3.8 (2.4) 6 (12) 4.9 (2.9) 1 (10) 3.5 (1.9) 2 (13) 3.3 (2.8) 3 (23) 3.7 (2.2) 0 (0)
W8 38/55 (69) 3.7 (2.0) 6 (12) 4.3 (2.3) 1 (10) 3.3 (2.0) 2 (13) 3.1 (1.9) 3 (23) 4.1 (2.0) 0 (0)
W9 42/55 (76) 3.7 (2.2) 6 (12) 4.4 (2.0) 1 (10) 3.4 (2.4) 2 (13) 3.3 (1.7) 3 (23) 4.0 (2.4) 0 (0)
W10 40/55 (73) 3.2 (2.4) 7 (14) 4.2 (2.5) 1 (10) 2.5 (1.9) 2 (13) 2.1 (1.6) 3 (23) 3.9 (2.9) 1 (6)
W11 39/55 (71) 3.4 (2.3) 8 (16) 4.3 (1.4) 1 (10) 2.3 (1.8) 2 (13) 2.7 (1.5) 3 (23) 4.5 (3.1) 2 (12)
W12 32/55 (58) 2.9 (2.1) 9 (18) 3.1 (1.9) 1 (10) 2.4 (1.4) 3 (20) 2.5 (1.9) 3 (23) 3.8 (3.1) 2 (12)
FU 36/55 (65) 3.4 (2.5) NA 5.2 (2.5) NA 2.7 (1.5) NA 3.0 (2.1) NA 3.0 (3.2) NA
BL baseline, W week, FU follow up questionnaire, SD standard deviation, NA not applicable. As a result of automated SMS sending errors and host network
availability errors, some participants were not sent all messages as described in the protocol. Results were based on 55 participants received all SMS/phone during
follow-up (SMA, n = 10; SMA-exercises, n = 15; SMA-orthoses, n = 13; SMA-combined, n = 17). ‘Significantly better’ is based on cumulative time taken to
consecutive weekly NRS response scores of 0 and/or 1




Fig. 2 Summary NRS Pain across 12 weeks follow-ups; Kaplan-Meier curves for ‘significantly better’ by treatment arm. a Summary mean pain scores. b
Life-Table graph for SMS pain NRS time-to-event (pain resolution) with straight-line interpolation. c Kaplan-Meier graph for SMS pain NRS time-to-event
(pain resolution) with stepped-line interpolation
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Baseline variables bilaterally correlated (rs ≥ 0.3) with
change in pain NRS were pain NRS (0.41) and FFI-Pain
(0.31) and with change in FFI-Pain were sex (0.39) and
pain NRS (0.33). No baseline variables were correlated
with change in MFPDI-Pain. Stepwise (backward/forward)
multivariable regression models for change in pain NRS (p
value cut-off 0.1) included baseline pain NRS, EQ-5D-5L
and age (r = 0.63). A multiple-correlation coefficient of r =
0.63 was obtained from a final stepwise regression model
for change in FFI-Pain including baseline FFI-Pain,
EQ5D-5L and first-ever episode of heel pain.
The exercise interventions were slightly more expen-
sive from UK-NHS and healthcare perspectives and from
a societal perspective including work absenteeism costs
only, but costs were broadly comparable across the
intervention arms when work presenteeism was taken
into account (Table 5).
Discussion
The TREADON pilot and feasibility trial can inform the
design of a future substantive trial of exercise and orth-
oses for the management of PHP. All three participant
identification methods successfully recruited the target
number of participants within the required timescale, al-
though a larger target population was required than
planned. Baseline characteristics were comparable, al-
though population survey recruits were older and had
milder symptoms, and those recruited via GP consult-
ation more commonly had shorter duration and unilat-
eral heel pain. Loss-to-follow-up rates were acceptable
but could be improved by offering a wider range of mo-
dalities for communication with participants and data
collection such as online questionnaires and e-mails in a
future main trial.
All interventions were feasible and acceptable to par-
ticipants and clinicians. Both physiotherapists and podia-
trists were able to deliver the interventions to protocol,
although some physiotherapists reported lacking confi-
dence in modifying the orthoses and additional training
for physiotherapists in the main trial would be necessary.
Participants in the three clinician-supported intervention
arms attended a mean of 2.3 consultations, whereas the
protocol permitted up to 6 sessions. Clinician training in
the main trial would need to emphasise the importance
of using the full number of available sessions to
supervise and progress interventions and we would need
to work with participating NHS physiotherapy and po-
diatry services to ensure this is possible. Participant-
reported intervention satisfaction and credibility were
high in the three clinician-supported intervention arms
but lower in the SMA arm. Signal of efficacy was stron-
ger for SMA-combined and SMA-orthoses than SMA-
exercises, although adherence was lower in the SMA-
exercises arm. The exercise intervention in a future main
trial would need modification to incorporate strategies
to enhance adherence. Interestingly, adherence to exer-
cise was better in the SMA-combined arm than the
SMA-exercises arm, and the participant burden of re-
ceiving the combined intervention did not undermine
intervention adherence, satisfaction or credibility. There
were no unexpected or serious adverse events.
In terms of outcome measures, the completion rates,
responsiveness and correlation with other change scores
support using the pain intensity NRS or FFI-pain as the
primary outcome in a future main trial. Although
MFPDI-pain item completion was high, it is less attract-
ive in view of limited responsiveness which has been re-
ported previously [41, 42]. The pain NRS has the
additional advantage of facilitating weekly data collection
via SMS text message.
Strengths of the trial include the primary care setting
which ensures generalisability to most patients with
PHP, and the inclusion of four intervention arms which
included a self-management advice control arm and a
combined exercises and orthosis arm. The interventions
could be delivered by physiotherapists or podiatrists
making intervention delivery feasible and scalable for a
large future main trial. Limitations include lack of par-
ticipant blinding, common to many trials of non-
pharmacological interventions and collecting only self-
reported outcome and adherence data. Because of slow
initial recruitment, an amendment to the randomisation
ratio was made to ensure sufficient participants were re-
cruited to the clinician-supported interventions to allow
adequate assessment of their feasibility. Although the re-
cruitment target was reached, this required a larger
pooled practice population from which participants were
invited than predicted. The number of participants in
each arm was small, particularly in the control arm, lim-
iting the conclusions that can be drawn. The technical
issues encountered with the text message follow-ups,
whilst restricting the ability to fully assess the pain NRS
outcome measure, provided insight into the practical is-
sues concerning this data collection method. Whilst pa-
tients were involved in the development of the SMA
booklet, the booklet did not include information about
the association of PHP with anxiety and depression [2].
Conclusions
We have demonstrated the feasibility and acceptability
of conducting a future, main, randomised clinical trial to
investigate the clinical and cost-effectiveness of indivi-
dualised exercise and/or foot orthoses for PHP. Success
criteria concerning recruitment, intervention training
and delivery and adherence to, satisfaction with and
credibility of interventions were met. Key information to
inform participant identification, outcome measures and
sample size were obtained. Both physiotherapists and
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podiatrists delivered both types of intervention success-
fully, albeit with important learning for clinician training
and intervention delivery in the main trial. Descriptive
analyses of clinical outcomes provide signal of efficacy
and suggest these interventions are promising, and that
a future large trial would be informative for clinical
practice.
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